Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654051 | 0.88 | PPARG (0.55) | GCGRPPARG | |
| SCHEMBL2652504 | 0.80 | KDM4E (0.43) | GCGRPPARG | |
| SCHEMBL2651740 | 0.80 | PPARG (0.42) | GCGRPPARG | |
| SCHEMBL2651903 | 0.80 | HDAC1 (0.41) | GCGR | |
| SCHEMBL2653452 | 0.79 | RIPK2 (0.45) | PPARG | |
| SCHEMBL2651576 | 0.79 | EGLN1 (0.48) | GCGRPPARG | |
| SCHEMBL2651098 | 0.79 | KDM4E (0.46) | GCGRPPARG | |
| SCHEMBL7113992 | 0.78 | SMN1; SMN2 (0.43) | GCGRPPARG | |
| SCHEMBL2652239 | 0.76 | GCGR (0.40) | GCGRPPARG | |
| SCHEMBL2653039 | 0.75 | MRGPRX1 (0.51) | GCGRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCGR 2/4885PPARG 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.